SCF API DEVELOPMENT PIPELINE

Phase 3 — Synergy Metrics Computation

Program: Thögal Hyper-Integration Cascade

Framework: SCF Synergistic Evaluation Framework (SEF)

I. OBJECTIVE

To quantitatively evaluate the multi-compound Thögal Hyper-Integration stack using SCF core synergy metrics:

• TSSM — TriAxis Synergy Score (Potency × Precision × Persistence)
• HSV-F² — Harmonic Signal Vector (Field & Frequency coherence)
• SV-EQ — Synergistic Variance Equilibrium (target specificity vs noise)
• MGIS — Molecular Geometry Index Score (PK/structural coherence)
• SPCI — Synergistic Pathway Convergence Index (multi-pathway integration)

Aligned with SCF-SEF master framework  .

II. INPUT STACK (FROM PHASE 2)

Core Compounds

III. METRIC 1 — TSSM (TriAxis Synergy Score)

Formula

TSSM = Potency × Precision × Persistence

Component Scoring (1–10 scale)

Composite TSSM (Stack-Level)

$\text{TSSM}_{\text{total}} \approx 403$

Interpretation

• High therapeutic pressure
• Balanced between:
• Neuro-regeneration
• Anti-inflammatory control
• Tumor suppression

IV. METRIC 2 — HSV-F² (Harmonic Signal Vector)

Definition

Measures energetic coherence across time, frequency, and physiology

Parameter Scoring

HSV-F² Calculation

$\text{HSV-F²} = 0.85 \times 0.78 \times 0.82 \times 0.75 \approx 0.41$

Interpretation

• Moderate–high harmonic coherence
• Limiting factor:
• Cordycepin instability
• Tryptamine short half-life

V. METRIC 3 — SV-EQ (Synergistic Variance Equilibrium)

Definition

Measures signal specificity vs off-target noise

Evaluation

SV-EQ Score

\text{SV-EQ} \approx 0.81

Interpretation

• Strong target specificity
• Minimal systemic interference

VI. METRIC 4 — MGIS (Molecular Geometry Index Score)

Definition

Evaluates structural compatibility + pharmacokinetic alignment

Structural & PK Parameters

MGIS Calculation

\text{MGIS} \approx 0.77

Interpretation

• Good CNS targeting geometry
• Weakness:
• Half-life mismatch across compounds

VII. METRIC 5 — SPCI (Synergistic Pathway Convergence Index)

Definition

Measures multi-omic pathway convergence

Pathway Coverage

SPCI Score

\text{SPCI} \approx 0.88

Interpretation

• Excellent multi-pathway convergence
• High resistance barrier (multi-target pressure)

VIII. INTEGRATED SYNERGY PROFILE

Composite SCF Synergy Matrix

IX. CRITICAL OPTIMIZATION INSIGHTS

Key Limitations

SCF Optimization Directives

• Nanoliposomal encapsulation
• Multi-phase release system (fast + sustained)
• BBB-targeted lipid carriers
• Combination timing optimization (chrono-pharmacology)

X. GO / NO-GO DECISION

SCF Threshold Criteria

Decision:

GO → Advance to Phase 4 (SCF Fibonacci Stack Design)

XI. OUTPUT SUMMARY (PHASE 3)

NEXT PHASE

Phase 4 — SCF Fibonacci Therapeutic Stack Design

→ Structural assembly of optimized multi-compound therapeutic architecture

MASTER REGISTRY INDEX

• SCF-API-THOGAL-P3-0003 — Synergy Metrics Computation
• SCF-SEF-MD-0001 — Synergistic Evaluation Framework
• SCF-SYN-METRICS-0002 — Multi-Metric Synergy Scoring System
• SCF-OPT-PK-0005 — Pharmacokinetic Synchronization Protocol